在败血症相关的散布性血管内凝血中补充剂后影响抗血素活性的因素
Tomoki Tanigawa1,2, Toshiaki Iba3,4, Cheryl L Maier5
1Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. tanigawa-tomoki@jbpo.or.jp.
Thrombosis journal
|October 7, 2025
概括
在败血症相关的DIC患者中,较高的SOFA和FDP得分与治疗后较低的抗血素活性增加相关. 个性化剂量可能是必要的,因为基于体重的疗法没有显示出与出血风险的明显联系.
科学领域:
- 凝血和血栓形成的原因
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗血素对于调节凝血至关重要,并且在与败血症相关的传播性血管内凝血 (DIC) 中经常耗尽.
- 在日本,当活性下降到70%以下时,服用抗血素缩剂,但治疗后的变化是显著的.
- 影响抗血素活性变异性和出血风险的因素仍然不完全理解.
研究的目的:
- 为了确定治疗后抗血素活性水平的决定因素,在败血症相关的DIC患者中.
- 调查抗血素活性与出血风险之间的关系.
- 评估抗血素补充剂对生存结果的影响.
主要方法:
- 对与败血症相关的DIC中抗素度的营销后监测数据的回顾性分析.
- 计算每单位剂量 (IU/kg) 的抗血素活性变化.
- 后勤回归和卡普兰-梅尔生存分析,以评估影响活动的因素,出血风险和28天生存期.
主要成果:
- 分析了1,524名患者;中位数基线抗素活性为49%,在治疗后增加到74%.
- 较高的SOFA分数 (≥13) 和FDP水平 (≥25μg/mL) 与减少的抗素活性增加有关.
- 每IU/kg达到≥1%的活性增加与28天生存率的改善相关 (RR 0.72);没有发现剂量-活性-出血风险相关性.
结论:
- 升高的SOFA和FDP水平预测在败血症-DIC中对抗血补充剂的反应减少.
- 目前基于体重的剂量策略可能无法优化抗血素活性水平.
- 建议进行个性化抗血素剂量,以提高治疗疗效.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
01:29Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
01:24Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
01:16Clot Retraction and Fibrinolysis
8.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.4K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
12.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.1K